1.
Oncology
; 92(1): 55-60, 2017.
Artículo
en Inglés
| MEDLINE
| ID: mdl-27820931
RESUMEN
The combination of personalized therapy with immunotherapy might lead to rapid complete remission in patients who are too sick to be eligible for clinical trials. We report 2 such extraordinary responders. A discussion on the use and purpose of clinical trials in this new era of very active anticancer drug discovery concludes that a paradigm shift is urgently needed.